Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EMA Reviews Safety Of All Four Approved Vaccines, EU Buys Big On Comirnaty

Executive Summary

Calls grow for a relaxation of IP on COVID-19 vaccines as interest groups pile the pressure on the UK government and the Pope gives his blessing to the proposed waiver.

You may also be interested in...



EU Heart Condition Warning For COVID-19 Vaccines Comirnaty And Spikevax

All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.

Coronavirus Notebook: EMA OKs More Vaccine Production Plants, WHO Sounds Alert Over Africa

Vaxzevria should not be given to people who have had capillary leak syndrome, the EU regulator says. The G7 leaders have made big pledges on vaccine donations, and international regulatory bodies have issued a guide to shoring up confidence in vaccination.

COVID-19 Vaccines: Myocarditis Reports Could Slow Expansion Into Pediatric Age Groups

Concerns about cases of heart muscle inflammation occurring in older male adolescents and young men shortly after the second dose of Pfizer and Moderna mRNA vaccines hung over FDA advisory committee discussions on pediatric safety data requirements for COVID-19 vaccines; CDC’s ACIP will take up the myocarditis issue at an 18 June meeting.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel